Rare disease pioneer Ultragenyx buys out gene therapy company as it targets another malady

The deal includes a $75 million upfront payment and the promise of $115 million to GeneTx shareholders if the Angelman Syndrome therapy hits late-stage clinical and commercial milestones.

Source: bizjournals.com Health Care News Headlines - July 18, 2022 Category: Health Management Authors: Ron Leuty Source Type: news